Lillie D Shockney RN, BS, MAS, ONN-CGUniversity Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Founder, Academy of Oncology Nurse & Patient Navigators; Co-Developer, Work Stride — Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Baltimore, Maryland
Lillie D. Shockney served as the administrative director of the Johns Hopkins Breast Center from 1997 -2018 and served as the director of the Johns Hopkins Cancer Survivorship programs from 2011- 2018. A two-time breast cancer survivor, Lillie has worked tirelessly to improve the care of breast cancer patients around the world. She has worked at Johns Hopkins since 1983. Lillie is a published author and nationally recognized public speaker on the subject of cancer with a focus on cancer survivorship, preservation of quality of life, metastatic breast cancer, end of life planning and care, and improving the cancer patient’s experience. She has written 18 books and more than 350 articles on cancer care. Lillie is also editor-in-chief of Journal of Oncology Navigation and Survivorship. She is the co-founder and Program Director of the Academy of Oncology Nurse & Patient Navigators (AONN+) since its inception in 2009. She is the consultant for breast cancer for national ABC News and Good Morning America, and is also consulted regularly by the Today Show and CNN. Lillie serves on 34 medical advisory boards currently.
In 2008, The President of The Johns Hopkins University and the Johns Hopkins Board of Trustees appointed her to a chair as a University Distinguished Service Assistant Professor of Breast Cancer. This is the first time in the history of the institution that a hospital nurse has been appointed to a distinguished service designation. She was promoted to a Distinguished Service Associate Professor of Breast Cancer in 2009. In 2016, she was promoted to full professor and is the only nurse at Johns Hopkins to have a primary faculty appointment in the School of Medicine and the only nurse to have reached the highest academic faculty ranking and appointed to a faculty chair as a University Distinguished Service Professor of Breast Cancer.
In 2012, she and a colleague created an employee benefit called Work Stride- Managing Cancer at Work. It was so successful among Johns Hopkins employees and management that it now is offered nationally to other businesses and corporations, serving many large and midsize companies across the country. She continues her work within the Johns Hopkins Healthcare Solutions division of Johns Hopkins, to enhance the program and continue to support its growth.
She has received 60 awards—53 national awards and 7 state awards including being inducted into the Maryland Women Hall of Fame, Women in Business Healthcare Trailblazer Award, Johnson & Johnson’s Most Amazing Nurse in America award, National Komen for the Cure’s Professor of Survivorship award, and several national life time achievement awards. Her research area of focus is preservation of quality of life for patients with metastatic breast cancer.
Currently, a documentary is being made about her life and her life’s work. She tells people she never forgets where she came from—she will always be “a farmer’s daughter.”
- University Distinguished Service Professor of Breast Cancer
- Former Administrative Director, Johns Hopkins Breast Center
- Former Director, Johns Hopkins Cancer Survivorship Programs
- Professor of Surgery, Johns Hopkins University School of Medicine
- Co-Developer of Work Stride: Johns Hopkins Managing Cancer at Work Program
- Co-founder, the Academy of Oncology Nurse Navigators (AONN+)
RN Diploma, MacQueen Gibbs Willis School of Nursing, Easton Memorial Hospital, Easton, MD
BS in Health Care Administration, St. Joseph's College, Portland, Maine
Master of Administrative Science, Johns Hopkins University, Baltimore, Maryland
Clinical Interests:Quality-of life-issues for breast cancer survivors
DisclosuresLillie Shockney is on the speakers bureau for Pfizer Oncology.
Recent Contributions to PracticeUpdate:
- Improved Survival in MBC Over 20 Years at a Single Center
- Dual HER2 Blockade in the First-Line Treatment of Metastatic Breast Cancer
- High Absolute Lymphocyte Counts Are Associated With Longer Overall Survival in Patients With MBC Treated With Eribulin
- Individualized Prediction of Survival Benefit From Locoregional Surgical Treatment for Patients With Metastatic Breast Cancer
- Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer
- CDK4/6 Inhibitors for HR+ Breast Cancer
- Lapatinib and Treatment After Lapatinib in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
- Patient-Reported Outcomes From the IMpassion130 Trial of Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
- De Novo vs Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival
- Treatment Sequencing: A Critical Issue in Research and Clinical Practice